SCHEMBL23778233

SCHEMBL23778233

CCC1CN(C2CCC(C#N)(c3cccc(C)c3)CC2)CCCN1C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.44
KDM1A O60341 1/20 0.36
KDM2B Q8NHM5 2/20 0.36
PRKCB P05771 2/20 0.36
ALDH1A1 P00352 1/20 0.35
PDE4A P27815 2/20 0.35
PDE4B Q07343 2/20 0.35
PDE4C Q08493 2/20 0.35
PDE4D Q08499 2/20 0.35
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
CYP2C19 P33261 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
OPRM1 P35372 1/20 0.34
OPRD1 P41143 1/20 0.34
MAPK1 P28482 1/20 0.34
CCR2 P41597 1/20 0.33
OPRL1 P41146 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23778274 0.91 CYP2D6 (0.52) CYP2D6KDM1APRKCBALDH1A1MEN1
SCHEMBL23778279 0.90 CYP2D6 (0.49) CYP2D6KDM1APRKCBALDH1A1PDE4A
SCHEMBL23778249 0.90 CYP2D6 (0.43) CYP2D6KDM1AKDM2BPRKCBALDH1A1
SCHEMBL23778336 0.84 CYP2D6 (0.57) CYP2D6KDM1APRKCBALDH1A1PDE4A
SCHEMBL23778310 0.84 CYP2D6 (0.46) CYP2D6KDM1APRKCBPDE4APDE4B
SCHEMBL23778231 0.84 CYP2D6 (0.44) CYP2D6KDM1AKDM2BPRKCBALDH1A1
SCHEMBL23778251 0.84 PIK3CA (0.38) CYP2D6KDM2BPRKCB
SCHEMBL23778369 0.83 CYP2D6 (0.41) CYP2D6PRKCB
SCHEMBL23778427 0.83 CYP2D6 (0.48) CYP2D6KDM1AALDH1A1MEN1KMT2A
SCHEMBL23778283 0.83 CYP2D6 (0.44) CYP2D6KDM2BALDH1A1PDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3526207-B1 HETEROCYCLIC COMPOUNDS HAVING ACTIVITY AS MODULATORS OF MUSCARINIC M1 AND/OR M4 RECEPTORS IN THE TREATMENT OF CNS DISEASES AND PAINS. HEPTARES THERAPEUTICS LTD (GB) 2021-09-08 EP claimed